Colonial Trust Advisors Sells 19,072 Shares of Pfizer Inc. (NYSE:PFE)

Colonial Trust Advisors reduced its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 63.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,923 shares of the biopharmaceutical company's stock after selling 19,072 shares during the quarter. Colonial Trust Advisors' holdings in Pfizer were worth $290,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. PSI Advisors LLC grew its position in shares of Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after buying an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after acquiring an additional 391 shares during the period. D Orazio & Associates Inc. raised its position in Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after acquiring an additional 391 shares in the last quarter. Lipe & Dalton lifted its stake in Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC increased its stake in Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock worth $499,000 after purchasing an additional 401 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Remove Ads

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. UBS Group lowered their price target on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and an average target price of $31.07.

Pfizer Stock Up 0.9 %

NYSE PFE traded up $0.20 during trading on Monday, hitting $22.11. The stock had a trading volume of 50,694,569 shares, compared to its average volume of 40,315,662. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company's 50-day moving average price is $25.25 and its two-hundred day moving average price is $26.38. The company has a market capitalization of $125.40 billion, a PE ratio of 15.68, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.